-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35

Benzinga·09/21/2026 12:46:02
Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $32 to $35.